Acumen Research and Consulting estimates that global Antidiabetics market is expected to reach the market value of around US$ 75 Bn by 2027 and is anticipated to grow at a CAGR of around 10.3% in terms of revenue during the forecast period 2020-2027
Diabetes is a chronic metabolic condition in which the body cannot produce insulin (Type-1) because insulin (Type-2) is not available. Diabetes is a metabolic type of disease in which a person has elevated blood glucose (blood sugar) or body cells that do not respond sufficiently to insulin, or both. Increased thirst (polydipsia), weight loss, increased appetite (polyphagia), and increased and sweet-smelling urination (polyuria) can be seen in patients with elevated sugar levels. When diabetes is not treated, it causes a number of acute and life-threats.
The antidiabetic market contains drug that is also known as oral hypoglycemic / antihyperglycemic agents used for the diagnosis of diabetes mellitus. In recent years, the antidiabetics market has expanded tremendously, with the prevalence of diabetes mellitus increasing. Due to the growing number of diabetic individuals, systematic diabetes treatments have now become a focus problem in all income groups worldwide. Diabetes impacts medium-aged and adolescents. The report provides analysis of global antidiabetics market for the period 2016-2027, wherein 2020 to 2027 is the forecast period and 2019 is considered as the base year.
Market Insights
The global antidiabetic demand is powered by an ever-growing geriatric population, rising obesity among the public on numerous grounds, such as unhealthy eating habits and demanding and round-the-clock working conditions. Governments are likewise fueling business expansion programs to educate and increase awareness, enhance diabetes care, and innovate goods.
Many of the key drivers for this market growth include combinations of various medicines such as sitagliptin and metformin as well as other medicines in different stages during the process of clinical and pipeline production. Growing diabetes prevalence and new drug releases by major pharmaceutical firms are two of the main growth factors on this market.
Many of the major antidiabetic solution providers include a successful anti-diabetic pipeline and emerging companies, including the diabetes drug Tresiba by Novo Nordisk and the FDA clearance of Ryzodeg in September 2015. In fact, the Boehringer Ingelheim GmbH has a large diabetic drugs portfolio for patients with type II and elevated cardiovascular risk, such as Linagliptin (a dipeptidyl peptidase, DPP 4 inhibitor).
Nevertheless, all of these medicines have lost patent rights despite the existence of several antidiabetic branded medications. Despite immense demands from the government and the regulatory bodies that have banned top-selling medicines in multiple countries to allow lower quality generic drugs for diabetic patients. For eg, in November 2015, Mankind Pharma launched Dynaglipt (Teneligliphine), under DPP-4 inhibitors class in India for the middle to low revenue diabetic community.
The number of antidiabetics will then be moved to the market of first-generation pharmaceutical drugs and other generic medicines. In the case of antidiabetics which can treat many diabetes-related chronic diseases including cardiovascular disorders, dyslipidemia, hypertension etc., a significant unmet medical need has also been found. The lack in medication efficacy over a period and subsequent safety risks are another significant constraint in the antidiabetic market.
COVID-19 Impacts
There are many medical regimens globally to seek to find a trustworthy cure for Covid-19. The use of Hydroxychloroquine is a method of therapy while the second line of therapy focuses on the application of antiviral medications used to treat HIV infections. The market for novel antivirals and anti-inflammatory medications has risen with all these strategies. At present, the WHO has neither recommended nor consulted on any of these methods, whether one is better than the other.
Regional Stance
In 2019, the market for antidiabetics in North America had the highest share of the world. The high market success and the high standard of health insurance, understanding of the consumer, complexity of healthcare infrastructures and payment system are the main factors contributing to the widespread market penetration of conventional insulin drugs like long-acting, rapid-acts insulin analog and DPP-4 drug like Onglyza, Januvia, and Nesina.
Asia Pacific is expected to rise at the highest pace over the forecast era, owing to the increasingly growing rates of healthcare costs, the rising incidence of Type I and Type II diabetes and growing disposable patient income.
Key Players & Strategies
Participants include major global players Novartis AG, Novo Nordisk A/S, Johnson & Johnson, AstraZeneca, Merck & Co. Inc., Pfizer. Sanofi, and Others.
As a result of the introduction of innovative drugs such as Tresiba and the presence of a comprehensive distribution network in Asia Pacific, Western Europe and North America, Novo Nordisk held major market share.
Segmentation
Antidiabetics Market By Type
Insulin
- Long acting analog
- Rapid acting analog
- Short acting analog
- Premixed insulin
- Intermediate acting insulin
Drug class
- Alpha glucosidase inhibitors
- DPP-IV (Dipeptidyl Peptidase) inhibitors
- GLP-1 (Glucagon like peptide) agonists
- Sulphonylureas
- Biguanides
- Thiazolidinedione
- Meglitinides
- SGLT-II (Sodium Glucose Transport Proteins) inhibitors
Antidiabetics Market By Mode of Administration
Insulin syringe / Insulin pen
Insulin pump
Intravenous infusion
Oral
Others
Market By Region
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
CHAPTER 1. Industry Overview of Antidiabetics
1.1. Definition and Scope
1.1.1. Definition of Antidiabetics
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Antidiabetics Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Antidiabetics Market By Type
1.2.3. Antidiabetics Market By Mode of Administration
1.2.4. Antidiabetics Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Antidiabetics Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Antidiabetics Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Application Source of Antidiabetics Major Manufacturers in 2019
CHAPTER 5. Antidiabetics Market By Type
5.1. Introduction
5.2. Antidiabetics Revenue By Type
5.2.1. Antidiabetics Revenue (US$ Mn) and Forecast, By Type, 2016-2027
5.2.2. Insulin
5.2.2.1. Insulin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.2.1.1. Long acting analog
5.2.2.1.1.1. Long acting analog Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.2.1.2. Rapid acting analog
5.2.2.1.2.1. Rapid acting analog Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.2.1.3. Short acting analog
5.2.2.1.3.1. Short acting analog Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.2.1.4. Premixed insulin
5.2.2.1.4.1. Premixed insulin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.2.1.5. Intermediate acting insulin
5.2.2.1.5.1. Intermediate acting insulin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Drug class
5.2.3.1. Drug class Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.1.1. Alpha glucosidase inhibitors
5.2.3.2. Alpha glucosidase inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.2.1. DPP-IV (Dipeptidyl Peptidase) inhibitors
5.2.3.3. DPP-IV (Dipeptidyl Peptidase) inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.3.1. GLP-1 (Glucagon like peptide) agonists
5.2.3.4. GLP-1 (Glucagon like peptide) agonists Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.4.1. Sulphonylureas
5.2.3.5. Sulphonylureas Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.5.1. Biguanides
5.2.3.6. Biguanides Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.6.1. Thiazolidinedione
5.2.3.7. Thiazolidinedione Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.7.1. Meglitinides
5.2.3.8. Meglitinides Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.8.1. SGLT-II (Sodium Glucose Transport Proteins) inhibitors
5.2.3.9. SGLT-II (Sodium Glucose Transport Proteins) inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. Antidiabetics Market Revenue By Mode of Administration
6.1. Introduction
6.2. Antidiabetics Revenue (US$ Mn) By Mode of Administration
6.2.1. Antidiabetics Revenue (US$ Mn) and Forecast By End Use, 2016 - 2027
6.2.2. Insulin syringe/ Insulin pen
6.2.2.1. Insulin syringe/ Insulin pen Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. Insulin pump
6.2.3.1. Insulin pump Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.4. Intravenous infusion
6.2.4.1. Intravenous infusion Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.5. Oral
6.2.5.1. Oral Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.6. Others
6.2.6.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 7. North America Antidiabetics Market By Country
7.1. North America Antidiabetics Overview
7.2. U.S.
7.2.1. U.S. Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
7.2.2. U.S. Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
7.3. Canada
7.3.1. Canada Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
7.3.2. Canada Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
7.4. North America PEST Analysis
CHAPTER 8. Europe Antidiabetics Market By Country
8.1. Europe Antidiabetics Testing Services Market Overview
8.2. U.K.
8.2.1. U.K. Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.2.2. U.K. Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
8.3. Germany
8.3.1. Germany Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.3.2. Germany Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
8.4. France
8.4.1. France Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.4.2. France Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
8.5. Spain
8.5.1. Spain Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.5.2. Spain Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
8.6. Rest of Europe
8.6.1. Rest of Europe Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.6.2. Rest of Europe Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Antidiabetics Market By Country
9.1. Asia Pacific Antidiabetics Market Overview
9.2. China
9.2.1. China Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
9.2.2. China Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 - 2027
9.3. Japan
9.3.1. Japan Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
9.3.2. Japan Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 - 2027
9.4. India
9.4.1. India Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
9.4.2. India Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 - 2027
9.5. Australia
9.5.1. Australia Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
9.5.2. Australia Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 - 2027
9.6. South Korea
9.6.1. South Korea Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
9.6.2. South Korea Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 - 2027
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
9.7.2. Rest of Asia-Pacific Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 - 2027
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Antidiabetics Market By Country
10.1. Latin America Antidiabetics Market Overview
10.2. Brazil
10.2.1. Brazil Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.2.2. Brazil Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 - 2027
10.3. Mexico
10.3.1. Mexico Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.3.2. Mexico Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 - 2027
10.4. Rest of Latin America
10.4.1. Rest of Latin America Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
10.4.2. Rest of Latin America Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 - 2027
CHAPTER 11. Middle East & Africa Antidiabetics Market By Country
11.1. Middle East & Africa Antidiabetics Market Overview
11.2. Saudi Arabia
11.2.1. Saudi Arabia Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.2.2. Saudi Arabia Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 - 2027
11.3. UAE
11.3.1. UAE Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.3.2. UAE Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 - 2027
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.4.2. Rest of Middle East & Africa Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 - 2027
CHAPTER 12. PLAYER ANALYSIS OF STROKE MANAGEMENT
12.1. Antidiabetics Market Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Antidiabetics Market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. COMPANY PROFILE
13.1. Novartis AG
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (US$ Mn), 2019
13.1.3.2. Novartis AG 2019 Antidiabetics Business Regional Distribution
13.1.4. Product/ Service and Specification
13.1.5. Recent Developments & Business Strategy
13.1.6. Manufacturing Plant Footprint Analysis
13.2. Novo Nordisk A/S
13.3. Johnson & Johnson
13.4. AstraZeneca
13.5. Merck & Co. Inc.
13.6. Pfizer
13.7. Sanofi
13.8. Others